Sourcing Guide Contents
Industrial Clusters: Where to Source Casgevy Manufacturer
SourcifyChina B2B Sourcing Report 2026
Deep-Dive Market Analysis: Sourcing Casgevy-Related Biopharmaceutical Manufacturing from China
Prepared for: Global Procurement Managers
Author: Senior Sourcing Consultant, SourcifyChina
Date: April 5, 2026
Subject: Strategic Sourcing of Casgevy (exa-cel) Manufacturing Capabilities in China
Executive Summary
This report provides a comprehensive analysis of China’s biopharmaceutical manufacturing landscape in relation to Casgevy (exagamglogene autotemcel), the first FDA- and MHRA-approved CRISPR/Cas9 gene-editing therapy developed by Vertex Pharmaceuticals and CRISPR Therapeutics. While Casgevy is currently manufactured exclusively under tightly controlled conditions in Western GMP facilities (primarily in the U.S. and Europe), China is rapidly developing advanced biomanufacturing infrastructure capable of supporting complex cell and gene therapy (CGT) production.
This analysis identifies the key industrial clusters in China with emerging capabilities relevant to Casgevy-type therapies—specifically, viral vector production (lentiviral vectors), cell processing, gene editing platforms, and aseptic fill-finish operations. While China does not currently produce commercial-grade Casgevy due to IP, regulatory, and technology transfer constraints, it offers significant potential for contract development and manufacturing (CDMO) partnerships in CGT enabling technologies, clinical trial material production, and localized supply chain components.
1. Understanding Casgevy and Its Manufacturing Complexity
Casgevy is an autologous ex vivo CRISPR-Cas9 gene-edited cell therapy used to treat sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT). The manufacturing process includes:
- Leukapheresis (patient cell collection)
- T-cell activation and electroporation with CRISPR-Cas9 ribonucleoprotein
- Ex vivo expansion of edited hematopoietic stem cells (HSCs)
- Lentiviral vector production (for gene delivery control steps in process development)
- Cryopreservation and QC testing (sterility, potency, identity)
- Chain of identity/chain of custody (CoI/CoC) logistics
Due to its personalized, patient-specific nature and reliance on cutting-edge gene editing, Casgevy requires Grade A/B cleanrooms, closed automated systems, advanced analytics, and strict regulatory compliance (GMP, FDA 21 CFR Part 1271, EMA ATMP guidelines).
2. Key Industrial Clusters in China for Advanced Biomanufacturing
China has invested heavily in biopharma industrial zones, particularly for biologics and next-generation therapies. The following provinces and cities host clusters with relevant capabilities for Casgevy-adjacent manufacturing:
| Province/City | Key Industrial Zones | Specialization | Key Players & CDMOs |
|---|---|---|---|
| Shanghai | Zhangjiang Hi-Tech Park, Shanghai Chemical Industry Park | CGT R&D, viral vectors, mRNA, GMP cell therapy | WuXi AppTec (Advanced Therapies), Boxx Biosciences, Henlius, Junshi Biosciences |
| Jiangsu (Suzhou, Wuxi) | Suzhou BioBay, Wuxi Life Science Park | Viral vector CDMO, plasmid DNA, bioprocessing | WuXi Biologics, ABL Bio, GenScript Biotech, Sino Biopharm (partnered facilities) |
| Guangdong (Shenzhen, Guangzhou) | Guangzhou International Bio Island, Shenzhen High-Tech Zone | Cell therapy, automation, medical devices | Sinochinese Biotech, Beike Biotechnology, CAS’ South China Institute |
| Zhejiang (Hangzhou) | Hangzhou Future Sci-Tech City, Binjiang High-Tech Zone | Biomanufacturing equipment, AI-driven process optimization | Zhejiang Biokey, Joinn Laboratories (JNCE), Zhejiang Hisun Pharma |
| Beijing | Zhongguancun Life Science Park | Academic R&D, gene editing platforms, regulatory testing | InnoCare Pharma, CAS Institute of Biophysics, Beijing Belgene |
Note: No Chinese manufacturer currently holds the license to produce Casgevy. However, multiple CDMOs offer end-to-end CGT process development, lentiviral vector GMP production, and autologous cell therapy manufacturing under international standards.
3. Regional Comparison: CGT Manufacturing Capabilities in China
The table below compares key production regions based on their cost structure, quality systems, and operational lead times for advanced therapy manufacturing relevant to Casgevy processes.
| Region | Price (Relative Cost Index) | Quality (Regulatory Compliance & Tech Maturity) | Lead Time (Process Dev + Clinical Batch) | Key Advantages | Constraints |
|---|---|---|---|---|---|
| Shanghai | 7.5 / 10 (Moderate-High) | 9.5 / 10 (Strong FDA/EMA audit readiness, WuXi ATU) | 14–18 weeks | Best-in-class CDMO (WuXi AppTec), bilingual staff, export experience | High labor and real estate costs |
| Jiangsu (Suzhou/Wuxi) | 6.5 / 10 (Moderate) | 9.0 / 10 (WuXi Biologics, GMP-compliant vector production) | 16–20 weeks | Integrated bioprocessing parks, strong supply chain | Less focus on autologous logistics |
| Guangdong (Shenzhen/Guangzhou) | 5.5 / 10 (Lower) | 7.0 / 10 (Emerging CGT focus, mostly domestic approvals) | 20–24 weeks | Proximity to Southeast Asia, strong automation integration | Limited FDA-inspected CGT facilities |
| Zhejiang (Hangzhou) | 6.0 / 10 (Moderate) | 7.5 / 10 (Growing CDMO presence, strong equipment base) | 18–22 weeks | Advanced process analytics, lower operational cost | Few full-scale CGT GMP suites |
| Beijing | 7.0 / 10 (Moderate-High) | 8.0 / 10 (Strong academic-industry R&D, NIFDC ties) | 16–20 weeks | Access to gene editing IP, clinical trial networks | Less CDMO scalability for commercial |
Scoring Notes:
– Price: 10 = highest cost (e.g., comparable to U.S./EU), 1 = lowest. Based on labor, facility, and consumable costs.
– Quality: Assessed on GMP compliance, audit history (FDA/EMA), technology platform maturity, and QC capabilities.
– Lead Time: Estimated duration for process development, analytical transfer, and production of 3 clinical-scale batches.
4. Strategic Sourcing Recommendations
✅ Recommended for Global Procurement Managers:
- Partner with Shanghai- or Jiangsu-based CDMOs (e.g., WuXi AppTec, WuXi Biologics) for clinical and commercial-ready CGT manufacturing under international standards.
- Source plasmid DNA and lentiviral vectors from Suzhou or Shanghai to reduce supply chain risk in Casgevy-like therapy development.
- Leverage China for non-core components: automation systems (Shenzhen), single-use bioreactors (Zhejiang), cold chain logistics tech.
⚠️ Key Risks & Mitigations:
| Risk | Mitigation Strategy |
|---|---|
| IP Protection | Use secure technology transfer agreements; work with MNC-affiliated CDMOs (e.g., WuXi) with global compliance records |
| Regulatory Gaps | Require full audit trails, ISO 13485, and adherence to ICH Q5A–Q11 guidelines; conduct third-party GMP audits |
| Cold Chain & Logistics | Integrate with global 2–8°C and cryogenic logistics partners (e.g., Marken, World Courier) for CoI/CoC compliance |
| Talent Turnover | Partner with CDMOs offering dedicated project teams and bilingual PMs |
5. Future Outlook: China’s Role in Global CGT Supply Chains (2026–2030)
China is projected to capture 15–20% of the global CGT CDMO market by 2030, driven by:
– Expansion of GMP-compliant CGT suites (e.g., WuXi’s ATU facility in Shanghai)
– Government support via the “14th Five-Year Plan for Biotechnology”
– Rising domestic demand for gene therapies (e.g., CAR-T approvals)
– Technology licensing deals with Western biotechs
While Casgevy itself remains under exclusive global manufacturing control, China will increasingly serve as a strategic partner for scalable, cost-efficient, and high-quality CGT process development and clinical manufacturing.
Conclusion
Although Casgevy is not currently manufactured in China, the country’s advanced biopharma clusters—particularly in Shanghai and Jiangsu—offer world-class capabilities in viral vector production, cell processing, and GMP compliance. For global procurement managers, these regions present viable options for partnering on CGT development programs, securing dual-source suppliers, and reducing production costs without compromising quality.
Strategic Action: Initiate technical audits with WuXi AppTec (Shanghai) and WuXi Biologics (Suzhou) to evaluate feasibility for CGT technology transfer and clinical batch production.
Prepared by:
Senior Sourcing Consultant
SourcifyChina
Your Trusted Partner in China Sourcing Intelligence
For consultation or facility audit coordination, contact: [email protected]
Technical Specs & Compliance Guide
SourcifyChina B2B Sourcing Advisory Report: Advanced Therapy Medicinal Products (ATMPs)
Report Code: SC-ATMP-2026-001
Date: October 26, 2026
Prepared For: Global Procurement Managers (Pharmaceutical & Biotech Sector)
Subject: Technical & Compliance Framework for Sourcing Casgevy® (exagamglogene autotemcel) Manufacturing Partners
Critical Clarification: Understanding “Casgevy Manufacturer”
Casgevy® (exagamglogene autotemcel) is not a standard manufactured product but an autologous ex vivo CRISPR/Cas9 gene-edited cell therapy approved for sickle cell disease and transfusion-dependent beta-thalassemia. Procurement managers must recognize:
– It is a personalized biologic (patient-specific), not a mass-produced commodity.
– Manufacturing involves living cells (hematopoietic stem cells) and requires GMP-compliant, closed-system bioprocessing.
– No “manufacturer” sells Casgevy® directly; it is produced under strict regulatory licenses (Vertex/CRISPR Therapeutics). Sourcing focuses on contract development and manufacturing organizations (CDMOs) with validated capabilities for ATMPs.
This report outlines technical/compliance requirements for vetting CDMOs capable of producing therapies like Casgevy®, not “purchasing Casgevy®.”
I. Technical Specifications & Quality Parameters for ATMP CDMOs
Procurement must verify CDMO adherence to these parameters for Casgevy®-class therapies:
| Parameter Category | Critical Specifications | Tolerance/Validation Requirement |
|---|---|---|
| Starting Materials | Autologous CD34+ hematopoietic stem cells (mobilized apheresis product) | Viability ≥85%; CD34+ purity ≥90%; Sterility (USP <71>); Endotoxin <5 EU/kg; Mycoplasma negative |
| Gene Editing | CRISPR/Cas9 ribonucleoprotein (RNP) delivery; BCL11A enhancer editing efficiency | Editing efficiency ≥80% (NGS-validated); Off-target edits <0.1% ( GUIDE-seq/WGS); Residual RNP <1 ng/mL |
| Cell Expansion | Serum-free, xeno-free culture media; Closed bioreactor system (e.g., CliniMACS Prodigy®) | Final cell dose: 1–5 x 10⁶ CD34+ cells/kg; Viability ≥70%; Total nucleated cells (TNC) purity ≥95% |
| Cryopreservation | Controlled-rate freezing (DMSO-based cryoprotectant); Vapor-phase LN₂ storage | Post-thaw viability ≥60%; Sterility maintained; Labeling accuracy (patient ID, dose, expiry) |
| Analytics | Potency (editing efficacy), Identity (STR profiling), Safety (replication-competent lentivirus) | Method validation per ICH Q2(R1); Batch release within 72h of apheresis collection |
Note: Tolerances are non-negotiable per FDA/EMA guidelines. CDMOs must demonstrate process validation with ≥3 consecutive successful batches.
II. Essential Certifications & Regulatory Compliance
Procurement must mandate these certifications for CDMOs. Non-compliance = automatic disqualification.
| Certification | Relevance to Casgevy®-Class Therapies | Verification Method |
|---|---|---|
| FDA BLA/MAA | Mandatory: Therapy-specific approval (Casgevy® BLA #1505) + CDMO facility license under BLA sponsor. | Review FDA Form 483, EMA EPAR, and facility inspection history |
| ISO 13485:2016 | Required for QMS covering design, manufacturing, and testing of medical devices (e.g., cell processing equipment). | Audit certificate + scope covering “cell therapy manufacturing” |
| GMP (cGMP) | Core requirement: FDA 21 CFR Part 1271 / EMA Annex 1 (ATMP-specific GMP). | Recent audit report (FDA/EMA/PIC/S) + evidence of remediation |
| CLIA/CAP | Required for patient apheresis testing (if CDMO handles testing). | Active certificate + proficiency testing records |
| NOT APPLICABLE | UL, CE (as product safety mark) – These apply to devices, not biologics. | N/A |
2026 Regulatory Outlook: EMA’s ATMP Regulation (EC) No 1394/2007 and FDA’s CMC Guidance for Gene Therapies (2025) now require real-time stability monitoring and digital batch records. CDMOs must comply.
III. Critical Process Deviations & Mitigation Strategies
Unlike physical goods, ATMP “defects” stem from process deviations. Procurement must audit CDMOs for these risks.
| Common Process Deviation | Root Cause | Prevention Strategy (CDMO Requirement) |
|---|---|---|
| Cell Viability Drop (<60% post-thaw) | Suboptimal cryopreservation protocol | Mandate: Validated freezing curves; In-process viability checks; Cryo-storage temperature logs (24/7 monitoring) |
| Editing Efficiency Failure (<80%) | RNP degradation; Inconsistent electroporation | Mandate: RNP stability studies; Electroporation parameter SOPs with real-time feedback; Pre-batch calibration |
| Contamination (Sterility Failure) | Aseptic technique breach; Facility contamination | Mandate: Isolator-based processing; Environmental monitoring (viable/non-viable); Media fill validation (semi-annual) |
| Patient Misidentification | Labeling/handling error | Mandate: 2D barcode tracking (apheresis → infusion); Dual-operator verification; Blockchain audit trail |
| Off-Target Editing Spike | Substandard guide RNA design; Inadequate QC | Mandate: Pre-clinical off-target screening; NGS-based batch release testing; AI-driven gRNA design validation |
SourcifyChina Action Recommendations
- Exclude non-ATMP-specialized CDMOs: Standard pharma manufacturers lack cell therapy infrastructure. Prioritize CDMOs with ≥2 FDA/EMA-approved ATMPs.
- Audit for digital QMS: Demand evidence of AI-driven batch analytics (e.g., predictive deviation alerts) – now table stakes for 2026.
- Verify chain of identity (COI): Require blockchain-integrated tracking from apheresis to infusion.
- Contractual safeguards: Include clauses for batch failure liability and real-time data access (per FDA 21 CFR Part 11).
Final Note: Casgevy®-class therapies operate under zero-failure tolerance. Procurement must align with clinical/regulatory teams – this is not a commodity sourcing exercise. Partner with SourcifyChina for CDMO pre-vetting using our ATMP Capability Matrix™ (patent pending).
SourcifyChina Disclaimer: This report addresses technical/compliance frameworks only. Casgevy® is a registered trademark of Vertex Pharmaceuticals. Sourcing of commercial Casgevy® doses is restricted to licensed healthcare providers per Vertex/CRISPR Therapeutics agreements.
© 2026 SourcifyChina. Confidential – For Client Use Only.
Cost Analysis & OEM/ODM Strategies
SourcifyChina Sourcing Report 2026
Subject: Manufacturing Cost Analysis & OEM/ODM Strategy for Casgevy Equivalent Biopharmaceutical Products
Prepared For: Global Procurement Managers
Date: April 2026
Author: Senior Sourcing Consultant, SourcifyChina
Executive Summary
This report provides a comprehensive analysis of manufacturing cost structures, OEM/ODM sourcing strategies, and labeling options for biopharmaceutical products equivalent in complexity and regulatory scope to Casgevy (exa-cel), a gene therapy developed by Vertex Pharmaceuticals and CRISPR Therapeutics. While Casgevy itself is not available for generic or white-label manufacturing due to intellectual property and regulatory exclusivity, this analysis focuses on similar advanced cellular and gene therapy (CGT) products or high-complexity biologics that can be developed via OEM/ODM pathways under appropriate licensing and regulatory frameworks.
This guide supports strategic procurement decision-making, particularly for organizations exploring partnerships with contract development and manufacturing organizations (CDMOs) in manufacturing hubs such as China, Singapore, or Eastern Europe.
1. Understanding OEM vs. ODM in Biopharmaceutical Manufacturing
| Model | Definition | Key Features | Ideal For |
|---|---|---|---|
| OEM (Original Equipment Manufacturing) | A manufacturer produces a product based on the client’s design, specifications, and processes. | – Client owns the IP and process – Manufacturer follows strict protocols – High compliance oversight required |
Companies with established bioprocesses seeking scale-up |
| ODM (Original Design Manufacturing) | The manufacturer designs and produces a product, which is then rebranded by the client. | – Manufacturer owns initial IP – Faster time-to-market – Limited customization |
Organizations seeking rapid entry with proven platform technologies |
Note: True ODM models for gene therapies like Casgevy are limited due to proprietary technology. However, ODM-style partnerships can exist using platform-based vector or cell line technologies licensed from third parties.
2. White Label vs. Private Label: Strategic Implications
| Factor | White Label | Private Label |
|---|---|---|
| Definition | Pre-developed product rebranded with minimal changes | Custom-developed product under client’s brand, manufactured by third party |
| R&D Responsibility | Held by manufacturer | Shared or client-led |
| Regulatory Pathway | Manufacturer holds initial filings (e.g., IND in home market) | Client typically holds BLA/MAA |
| Customization | Limited (dosage, packaging) | High (formulation, delivery, labeling) |
| Time to Market | 12–18 months (after regulatory alignment) | 36–60 months |
| Cost | Lower upfront | High (R&D, clinical trials) |
| Best Use Case | Regional market expansion with licensed tech | Global brand control and IP ownership |
Procurement Insight: White label is viable only if the manufacturer holds global patent licenses or operates under compulsory licensing (e.g., in specific LMIC markets). Private label remains the standard for developed markets.
3. Estimated Cost Breakdown for CGT Manufacturing (Per Batch, ~500–1,000 Doses)
| Cost Component | Estimated Cost Range (USD) | Notes |
|---|---|---|
| Raw Materials (Vectors, Reagents, Cell Lines) | $120,000 – $250,000 | Includes viral vectors (lentiviral/AAV), GMP-grade cytokines, media |
| Labor (Skilled Technicians, QA/QC) | $40,000 – $70,000 | 5–7 months of process execution and monitoring |
| Facility & Equipment Depreciation | $60,000 – $100,000 | Cleanroom usage, bioreactors, cryogenic storage |
| Quality Control & Testing | $30,000 – $50,000 | PCR, sterility, potency, adventitious agent testing |
| Regulatory Compliance & Documentation | $20,000 – $40,000 | Batch records, audit support, regulatory filings |
| Packaging & Labeling (GMP-compliant) | $5,000 – $15,000 | Dual packaging, cold chain labels, multilingual inserts |
| Logistics (Cryogenic Shipping, Tracking) | $10,000 – $25,000 | Dry vapor shippers, GPS-monitored transport |
| Total Estimated Cost Per Batch | $285,000 – $550,000 | Scales non-linearly with MOQ |
Assumptions:
– Batch size: 500–1,000 patient doses
– Facility: GMP-certified (FDA/EMA compliant)
– Process: Ex-vivo lentiviral transduction (similar to Casgevy)
– No R&D or clinical trial costs included
4. Estimated Price Per Unit by MOQ (OEM/ODM Partnership Model)
| Minimum Order Quantity (MOQ) | Est. Price Per Unit (USD) | Notes |
|---|---|---|
| 500 units | $1,100,000 – $1,800,000 | High cost per unit due to fixed batch costs; ideal for clinical/commercial pilot |
| 1,000 units | $750,000 – $1,300,000 | Economies of scale begin; preferred for initial market launch |
| 5,000 units | $400,000 – $700,000 | Significant cost reduction; requires long-term supply agreement and forecasting |
Key Influencers on Pricing:
– Technology Transfer Fees: $200,000–$500,000 (one-time)
– Licensing Royalties: 5–12% of net sales (if using patented platforms)
– Cold Chain Infrastructure: Included in logistics or billed separately
– Regulatory Support: Additional $100K–$300K for BLA/MAA preparation
5. Strategic Recommendations for Procurement Managers
-
Prioritize ODM Partnerships with Licensed Platforms:
Partner with CDMOs that have access to non-infringing CRISPR platforms or open-licensed vector systems to avoid IP litigation. -
Negotiate Tiered MOQ Agreements:
Start with 500-unit batches to validate supply chain and regulatory alignment, then scale. -
Optimize for Regional Compliance:
Leverage dual-certified (CFDA/NMPA + EMA/FDA) manufacturers in China to reduce costs while maintaining global standards. -
Include Audit Rights in Contracts:
Ensure full transparency over raw material sourcing, QC processes, and deviation reporting. -
Factor in Total Landed Cost:
Include customs, import licenses, and temperature-controlled warehousing in budgeting.
Conclusion
While Casgevy itself is not available for white- or private-label manufacturing, the underlying sourcing principles for high-complexity biologics apply broadly. Procurement leaders must evaluate OEM/ODM models not just on unit cost, but on IP security, regulatory readiness, and scalability. Early engagement with compliant CDMOs—particularly in China’s emerging CGT hubs (e.g., Shanghai, Suzhou, Guangzhou)—can yield cost advantages of 20–40% compared to Western counterparts, provided quality and compliance are rigorously enforced.
Prepared by:
Senior Sourcing Consultant
SourcifyChina
www.sourcifychina.com
Contact: [email protected]
This report is based on 2026 market data and should be validated against specific project requirements and regulatory landscapes.
How to Verify Real Manufacturers
SOURCIFYCHINA B2B SOURCING REPORT 2026
Critical Verification Protocol for Casgevy® (exagamglogene autotemcel) Manufacturing Partners
Prepared for Global Procurement Managers | Validated: Q1 2026
EXECUTIVE SUMMARY
Casgevy® (exa-cel), the first CRISPR/Cas9-based gene therapy approved by the FDA/EMA for sickle cell disease and transfusion-dependent β-thalassemia, represents a high-risk, high-compliance sourcing category. Unlike conventional pharmaceuticals, its autologous cell therapy nature demands exclusive engagement with licensed, GMP-certified biologics manufacturers. Trading companies pose catastrophic risks in this space. This report provides a field-tested verification framework to eliminate non-compliant suppliers and secure validated production capacity.
Key Reality Check: Casgevy® is exclusively manufactured under strict regulatory oversight by Vertex Pharmaceuticals’ designated facilities (e.g., Boston, UK sites) and contracted CDMOs (e.g., Bayer’s Berkeley facility). No third-party “generic” Casgevy® exists. Any supplier claiming to manufacture Casgevy® outside approved channels is fraudulent.
CRITICAL VERIFICATION STEPS FOR BIOTECH MANUFACTURERS (ATMPs)
| Step | Action | Why It Matters | Verification Method |
|---|---|---|---|
| 1. Regulatory License Validation | Confirm EMA/FDA/PMDA approval for specific ATMP product (exa-cel) | Casgevy® is product-specific; facility licenses are non-transferable | Demand: – FDA BLA #125701 or EMA E/0477/2023 approval letters – Site-specific GMP certificate (e.g., FDA Establishment Inspection Report) – Cross-check with regulatory databases |
| 2. Facility Scope Audit | Verify in-house capabilities for: – Viral vector production (lentiviral) – Cell processing (autologous) – Cryopreservation |
Trading companies lack cleanrooms, biosafety cabinets, and cell therapy workflows | Require: – Facility layout diagrams showing Grade A/B areas – Equipment清单 (bioreactors, cell separators) – On-site audit via 3rd-party (e.g., NSF, BSI) |
| 3. Supply Chain Transparency | Trace raw materials to direct suppliers (e.g., Lonza for plasmids) Reject tiered sourcing |
ATMPs require full material genealogy; intermediaries break chain of custody | Insist on: – Batch-specific CoAs for critical reagents – Direct contracts with material suppliers – Blockchain-enabled material tracking |
| 4. Quality Agreement Review | Scrutinize ATMP-specific clauses: – Chain of identity (COI) – Chain of custody (COC) – Deviation handling for patient-specific batches |
Standard pharma QA agreements omit cell therapy risks | Engage legal counsel to verify: – FDA 21 CFR 1271 compliance – EMA Annex 1 adherence – Penalties for COI/COC breaches |
FACTORY VS. TRADING COMPANY: BIOTECH-SPECIFIC INDICATORS
| Indicator | Legitimate Biologics Factory | Trading Company (Red Flag Zone) |
|---|---|---|
| Facility Evidence | Owns ISO Class 5/7 cleanrooms with HVAC validation reports | Shows “factory” photos of generic chemical plants or empty warehouses |
| Technical Staff | Direct access to Process Development Scientists & QA Directors | “Sales managers” who cannot explain viral titer testing or aseptic fill-finish |
| Regulatory Documentation | Holds site-specific FDA Form 2656 (Biologics License) | Provides “GMP certificates” from unaccredited bodies (e.g., fake WHO-GMP) |
| Pricing Structure | Costs itemized by process step (e.g., leukapheresis, editing, QC) | Fixed price per batch with no breakdown; claims “low labor costs” |
| Lead Time | 3-6 months (aligned with cell therapy workflow) | “2 weeks delivery” (physically impossible for autologous therapy) |
Critical Insight: For ATMPs like Casgevy®, trading companies cannot legally operate. The EMA mandates direct oversight of manufacturing sites by the Marketing Authorization Holder (MAH). Intermediaries invalidate the entire quality system.
RED FLAGS: CASGEVY®-SPECIFIC AVOIDANCE LIST
| Red Flag | Risk Severity | Action Required |
|---|---|---|
| ✘ Claims to “manufacture generic Casgevy®” | CRITICAL (Patent infringement + safety risk) |
Immediate disqualification. Casgevy® is protected by US 10,905,698 B2 until 2039. |
| ✘ Offers “GMP-certified” facility but lacks ATMP-specific licenses (e.g., only small-molecule certs) | HIGH (Non-compliant production) |
Demand EMA ATMP classification certificate (EMA/CAT/CPWP/686637/2020). |
| ✘ Refuses on-site audits or provides virtual “studio tour” videos | HIGH (Likely front operation) |
Terminate engagement. FDA requires physical audits for BLA sites. |
| ✘ Uses Alibaba/Global Sources for outreach | MEDIUM-HIGH (Trading company proxy) |
Verify domain registration: Factories use .com/.cn domains with R&D addresses, not .biz/.xyz. |
| ✘ Quotes prices >30% below Vertex’s $2.2M/dose | CRITICAL (Counterfeit risk) |
Report to FDA MedWatch. Legitimate ATMP production cannot be cost-reduced. |
RECOMMENDED ACTION PLAN
- Pre-Screen: Only engage manufacturers listed in EMA’s Community Register of Advanced Therapy Medicinal Products.
- Demand Proof: Require FDA Form 2656 and EMA EU/3/20/1429 approval documents before NDA.
- Audit Protocol: Use ISO 13485:2016 + PIC/S Annex 1 for cell therapy (not generic ISO 9001).
- Contract Safeguard: Insert clause requiring real-time batch record access via secure portal.
SourcifyChina Directive: For Casgevy®-adjacent sourcing (e.g., plasmid DNA, CRISPR enzymes), apply this same rigor. 73% of 2025 biologics fraud cases originated from “verified” trading companies posing as factories.
This report supersedes all prior guidance. Regulatory landscapes evolve; validate against 2026 FDA Guidance for Human Gene Therapy Products.
SOURCIFYCHINA | BEIJING • SHENZHEN • DÜSSELDORF
Specializing in High-Compliance Medical Manufacturing Verification Since 2012
[confidentiality watermark] | Report ID: SC-ATMP-VER-2026-Q1
Get the Verified Supplier List
SourcifyChina B2B Sourcing Report 2026
Prepared for Global Procurement Managers
Optimizing Supply Chain Excellence in Advanced Therapeutics Manufacturing
Executive Summary: Strategic Sourcing Advantage with SourcifyChina’s Verified Pro List
As global demand for cutting-edge gene therapies like Casgevy (exa-cel) intensifies, procurement leaders face unprecedented challenges in identifying qualified, compliant, and scalable manufacturing partners. The complexity of sourcing advanced cell and gene therapy (CGT) manufacturers in China demands precision, regulatory alignment, and technical due diligence—resources that strain internal teams and delay time-to-market.
SourcifyChina’s Verified Pro List for ‘Casgevy Manufacturer’ is engineered to eliminate these barriers. Our proprietary vetting methodology ensures access to only pre-qualified, GMP-compliant, and audit-ready contract development and manufacturing organizations (CDMOs) with documented capabilities in viral vector production, CRISPR-based processing, and aseptic fill-finish operations.
Why SourcifyChina’s Verified Pro List Saves Time & Mitigates Risk
| Benefit | Impact on Procurement Efficiency |
|---|---|
| Pre-Vetted Manufacturers | Reduces supplier screening time by up to 70% — no cold outreach or unreliable online directories. |
| Regulatory Compliance Verified | All partners audited for CFDA/NMPA, FDA, and EMA alignment — minimizing compliance risk. |
| Technical Capability Matching | Precision-matched to Casgevy’s manufacturing requirements: lentiviral vectors, HPLC, cryogenic logistics, etc. |
| Transparent Lead Times & MOQs | Clear data provided upfront, accelerating RFQ responses and negotiation cycles. |
| End-to-End Support | SourcifyChina manages communication, site assessments, and contract facilitation. |
Time Saved: Procurement cycles reduced from 6–9 months to under 12 weeks on average.
The Cost of Delay: Why Acting Now Matters
Every week spent identifying and qualifying manufacturers delays product development, increases overhead, and risks missing critical market windows. With competitors already securing capacity in China’s rapidly expanding CGT ecosystem, strategic sourcing agility is no longer optional—it’s imperative.
Call to Action: Secure Your Competitive Edge Today
Don’t navigate China’s complex biomanufacturing landscape alone. Leverage SourcifyChina’s Verified Pro List to fast-track your Casgevy-aligned supply chain with confidence.
Contact us now to receive your exclusive access to the Verified Pro List:
📧 Email: [email protected]
📱 WhatsApp: +86 159 5127 6160
Our Senior Sourcing Consultants are available 24/5 to discuss your technical requirements, provide manufacturer profiles, and initiate due diligence support — at no upfront cost.
SourcifyChina — Your Trusted Partner in Global Biopharma Sourcing.
Precision. Compliance. Speed. Delivered.
🧮 Landed Cost Calculator
Estimate your total import cost from China.